Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Half effective dose of ciprofol to inhibit endoscope insertion reaction during gastroscopy
ChiCTR2200056608Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Guizhou Medical University
- Start
- Feb 2022
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ciprofol in upper gastrointestinal endoscopy complication (2 arms), sponsored by Affiliated Hospital of Guizhou Medical University. Primary endpoint: Endoscope insertion reaction. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
ciprofol
03
Conditions
upper gastrointestinal endoscopy complication
Beyond the preview
Go deeper on ChiCTR2200056608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056608.